Zenith Capital (Zenith Capital) Dividend Payout Ratio : 0.00 (As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Dividend Payout Ratio?

Zenith Capital's dividend payout ratio for the months ended in . 20 was 0.00.

The historical rank and industry rank for Zenith Capital's Dividend Payout Ratio or its related term are showing as below:

ZHCLF's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.44
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-06-04), the Dividend Yield % of Zenith Capital is 0.00%.

Zenith Capital's Dividends per Share for the months ended in . 20 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Zenith Capital Dividend Payout Ratio Historical Data

The historical data trend for Zenith Capital's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Dividend Payout Ratio Chart

Zenith Capital Annual Data

Trend

Dividend Payout Ratio

Zenith Capital Quarterly Data

Dividend Payout Ratio

Competitive Comparison of Zenith Capital's Dividend Payout Ratio

For the Biotechnology subindustry, Zenith Capital's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenith Capital's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Zenith Capital's Dividend Payout Ratio falls into.

Zenith Capital Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Zenith Capital's Dividend Payout Ratio for the fiscal year that ended in . 20 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: . 20 )	/	EPS without NRI (A: . 20 )
	=		/
	=	N/A

Zenith Capital's Dividend Payout Ratio for the quarter that ended in . 20 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: . 20 )	/	EPS without NRI (Q: . 20 )
	=		/
	=	N/A

Zenith Capital (OTCPK:ZHCLF) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Zenith Capital Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines